Promising Clinical Developments in Rocket Pharmaceuticals Justify Buy Rating and $52 Target Price
Rocket Pharmaceuticals (RCKT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum ...
Promising Phase 1 Trial Data and Market Potential Propel Buy Rating for Rocket Pharmaceuticals’ RP-A501 Gene Therapy
Jason Zemansky, an analyst from Bank of America Securities, reiterated the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...